Health Claims

The improvements in how the body uses insulin didn't relate to changes in fat stored in organs or specific body areas. This finding is from the abstract summary - full study details were not available

Correlational

The exercise program didn't affect fat stored in organs like the liver or muscles in these women. This finding is from the abstract summary - full study details were not available

Descriptive

Regular exercise helped reduce fat around the hips and thighs in obese black South African women. This finding is from the abstract summary - full study details were not available

Causal

After exercising regularly for 12 weeks, the women's bodies became better at using insulin to manage blood sugar levels. This finding is from the abstract summary - full study details were not available

Causal

Doing regular exercise for 12 weeks helped improve heart and lung fitness in obese black South African women, as measured by their ability to use oxygen during exercise. This finding is from the abstract summary - full study details were not available

Causal

For HIV patients with belly fat on tesamorelin, losing belly fat was linked to better muscle density in their abdominal and rectus muscles.

Correlational

HIV patients with belly fat who responded to tesamorelin had more lean muscle mass in all four trunk muscles, with increases between 0.64 and 1.08 cm² compared to placebo after 26 weeks.

Quantitative

HIV patients with belly fat who responded to tesamorelin had bigger rectus and psoas muscles (0.44 and 0.46 cm² larger) compared to placebo after 26 weeks.

Quantitative

HIV patients with belly fat who responded to tesamorelin saw better lean muscle quality in their abdominal and rectus muscles, with improvements of 1.39 and 1.78 units respectively compared to placebo after 26 weeks.

Quantitative

For HIV patients with belly fat who responded to tesamorelin, the drug was linked to better muscle density in four trunk muscles, with improvements between 1.56 and 4.86 units compared to placebo after 26 weeks.

Quantitative

For HIV patients with belly fat and high liver enzymes, losing visceral fat improved liver enzymes whether they had hepatitis or not.

Correlational

HIV patients with belly fat who took tesamorelin were more likely to lose at least 8% of their visceral fat than those who took a placebo.

Correlational

HIV patients with belly fat and high liver enzymes had more visceral fat and less fat under the skin than those with normal liver enzymes.

Correlational

Whether HIV patients had hepatitis or not didn't change the link between losing visceral fat and improving liver enzymes.

Correlational

In people with HIV and belly fat, higher amounts of visceral fat at the start were linked to higher liver enzyme levels.

Correlational

For HIV patients with high liver enzymes taking a placebo, losing visceral fat didn't lead to better liver enzyme levels.

Correlational

HIV patients with belly fat and high liver enzymes who lost at least 8% visceral fat were more likely to have their ALT levels return to normal after 6 months than those who didn't lose that much fat.

Correlational

HIV patients with high liver enzymes who lost visceral fat from tesamorelin kept their liver enzyme improvements for a full year even after stopping the drug, even though some fat came back.

Correlational

HIV patients with belly fat and high liver enzymes who lose at least 8% of visceral fat see a bigger drop in AST levels than those who don't lose that much fat.

Correlational

For people with HIV and belly fat who have high liver enzyme levels, those who lose at least 8% of their visceral fat see a bigger drop in ALT levels than those who don't lose that much fat.

Correlational

HIV patients on medication who keep taking tesamorelin for a year continue to have less belly fat, lower triglycerides, and better cholesterol levels compared to when they started. This finding is from the abstract summary - full study details were not available

Causal

People with HIV on medication who take tesamorelin feel better about their belly appearance, as both they and their doctors report improvements. This finding is from the abstract summary - full study details were not available

Causal

Tesamorelin improves the ratio of bad cholesterol to good cholesterol by about 7% in HIV patients on medication, which is better for heart health. This finding is from the abstract summary - full study details were not available

Causal

Tesamorelin helps lower triglycerides, a type of fat in the blood, by about 12% in HIV patients on medication compared to those not taking it. This finding is from the abstract summary - full study details were not available

Causal